Pharmaceuticals, Biotechnology & Life Sciences

Centessa Pharmaceuticals’ acquisition by Eli Lilly shows how big pharma is turning to data‑driven biotech to refresh pipelines, boost sleep‑disorder treatments and navigate patent expirations amid regulatory uncertainties.

Explore iX Biopharma’s journey from pioneering pain‑management wafers like Wafermine to nutraceuticals, amid market volatility and a challenging P/E ratio.

Vanda Pharmaceuticals urges FDA to withdraw FY 2027 review‑timeline extension, fearing delays to its CNS drug pipeline and investor confidence.

Assertio Holdings’ acquisition by Garda sparks mixed analyst sentiment—can a $125M deal turn its negative earnings into profit? Discover the risks and upside.

iX Biopharma Ltd. explores breakthrough pain‑management wafers in Singapore and beyond, balancing cutting‑edge innovation with volatile financial performance.

AbCellera Biologics: a Canadian biotech innovator in therapeutic antibodies—new Jones Trading buy, $1B cap, cutting‑edge tech, promising growth in drug discovery.

Replimune’s second FDA rejection of its RP1 melanoma therapy forces a strategic overhaul—stock drops, layoffs hit, and the company must reshape trials or pivot its pipeline for survival.

Codexis, a biotech leader in biocatalyst tech, fuels greener pharma & fine‑chemical production—yet faces profitability hurdles amid market shifts.

Discover why Anavex Life Sciences, a Nasdaq biotech focused on precision genetic medicine, is facing financial challenges and investor uncertainty.

BioNTech’s trastuzumab pamirtecan shows 48% response in HER2‑positive recurrent endometrial cancer, while a new Boehringer partnership targets small‑cell lung cancer, and a €1.9 bn court win boosts its oncology pivot.